Lin Wei - 16 Jun 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders, as Attorney-in-fact for Wei Lin
Issuer symbol
RVMD
Transactions as of
16 Jun 2025
Net transactions value
-$86,551
Form type
4
Filing time
18 Jun 2025, 16:05:01 UTC
Previous filing
15 May 2025
Next filing
18 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wei Lin Chief Medical Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as Attorney-in-fact for Wei Lin 18 Jun 2025 0001872772

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale $86,551 -2,173 -2.3% $39.83 90,499 16 Jun 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
F2 This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
F4 Includes 64,800 RSUs.